Compare FRGT & JAGX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | FRGT | JAGX |
|---|---|---|
| Founded | 2015 | 2013 |
| Country | Mexico | United States |
| Employees | N/A | N/A |
| Industry | Professional Services | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 2.6M | 2.2M |
| IPO Year | 2021 | 2014 |
| Metric | FRGT | JAGX |
|---|---|---|
| Price | $3.71 | $2.16 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 1 |
| Target Price | N/A | ★ $60.00 |
| AVG Volume (30 Days) | ★ 96.3K | 65.3K |
| Earning Date | 05-20-2026 | 04-07-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 96.85 | 82.42 |
| EPS | ★ N/A | N/A |
| Revenue | ★ $13,728,922.00 | $11,511,000.00 |
| Revenue This Year | $371.03 | $61.58 |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $0.50 | $0.22 |
| 52 Week High | $5.19 | $8.00 |
| Indicator | FRGT | JAGX |
|---|---|---|
| Relative Strength Index (RSI) | 55.68 | 41.47 |
| Support Level | $0.80 | $1.78 |
| Resistance Level | $4.94 | $2.43 |
| Average True Range (ATR) | 0.49 | 0.27 |
| MACD | -0.17 | -0.14 |
| Stochastic Oscillator | 49.10 | 9.85 |
Freight Technologies Inc is a technology company developing solutions to optimize and automate the supply chain process. Along with its subsidiary, Freight App, Inc, the group is focused on making shipping transparent and efficient. Fr8App provides carriers with increased growth opportunities and shippers with flexibility, visibility, and simplicity for the once-complex process of international over-the-road (OTR) shipping. The company uses its proprietary technology platform to connect carriers and shippers and significantly improve matching and operation efficiency via technologies such as live pricing and real-time tracking, digital freight marketplace, broker, transportation management, fleet management, and committed capacity solutions.
Jaguar Health Inc is a commercial-stage pharmaceutical company developing novel proprietary prescription medicines sustainably derived from plants from rainforest areas for gastrointestinal disease states in humans and animals. The Company focuses on conditions associated with overactive bowel, including chronic debilitating diarrhea, urgency, and bowel incontinence. It operates through two segments: animal health, which develops and commercializes products for animals, and human health, with the human health segment generating the maximum revenue and focusing on products such as Mytesi, focusing on human products, specifically Mytesi, approved for symptomatic relief of non-infectious diarrhea in adults with HIV/AIDS on antiretroviral therapy.